ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

ClinicalTrials.gov ID: NCT00940225

Public ClinicalTrials.gov record NCT00940225. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 8:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors

Study identification

NCT ID
NCT00940225
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Exelixis
Industry
Enrollment
730 participants

Conditions and interventions

Interventions

  • Cabozantinib Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2009
Primary completion
Apr 30, 2013
Completion
May 31, 2014
Last update posted
Apr 24, 2024

2009 – 2014

United States locations

U.S. sites
34
U.S. states
23
U.S. cities
33
Facility City State ZIP Site status
Pinnacle Oncology of Arizona Scottsdale Arizona 85258
University of California Davis Cancer Center Sacramento California 95817
University of California, San Francisco San Francisco California 94115
Stanford University Medical Center Stanford California 94305
Rocky Mountain Cancer Centers Denver Colorado 80218
Yale University School of Medicine New Haven Connecticut 06520
Florida Cancer Specialists Fort Myers Florida 33916
Mount Sinai Comprehensive Cancer Center Miami Beach Florida 33140
Medical College of Georgia Augusta Georgia 30912
Central Indiana Cancer Centers Indianapolis Indiana 46227
Tulane University Health Sciences Center New Orleans Louisiana 70112
Dana Farber Cancer Center Boston Massachusetts 02115
University of Michigan Health System Ann Arbor Michigan 48109
Wayne State University Detroit Michigan 48201
University of Missouri Health Care Columbia Missouri 65203
Kansas City Cancer Center Lee's Summit Missouri 64064
Midwest Hematology Oncology Consultants St Louis Missouri 63136
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
NYU Clinical Cancer Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10065
Duke University Medical Center Durham North Carolina 27710
Ohio State University GYN Oncology Hilliard Ohio 43026
University of Oklahoma Oklahoma City Oklahoma 73190
Cancer Care Associates Tulsa Oklahoma 74104
Northwest Cancer Specialists Tualatin Oregon 97062
University of Pennsylvania Philadelphia Pennsylvania 19104
Cancer Centers of the Carolinas, ITOR Greenville South Carolina 29605
Sarah Cannon Research Institute Nashville Tennessee 37203
Texas Oncology - Central Austin Cancer Center Austin Texas 78731
Mary Crowley Medical Research Center Dallas Texas 75246
University of Texas, M. D., Anderson Cancer Center Houston Texas 77030
Tyler Cancer Center Tyler Texas 75702
Fairfax Northern Virginia Hematology Oncology Fairfax Virginia 22031
University of Washington Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00940225, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 24, 2024 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00940225 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →